Skip to content

Exploring the Pharmacomicrobiomics of Depression

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518101-18-02
Acronym
NL79264.091.21
Enrollment
25
Registered
2025-01-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

The primary outcomes are the association between medication induced changes in gut microbial profile, depression symptoms and side effects

Detailed description

A secondary outcome is the role of therapeutic blood plasma levels (reflecting drug absorption) in the association between medication-induced changes in the gut microbial profile and treatment efficacy.

Interventions

DRUGVENLAFAXINE

Sponsors

Radboud universitair medisch centrum Stichting
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
The primary outcomes are the association between medication induced changes in gut microbial profile, depression symptoms and side effects

Secondary

MeasureTime frame
A secondary outcome is the role of therapeutic blood plasma levels (reflecting drug absorption) in the association between medication-induced changes in the gut microbial profile and treatment efficacy.

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026